查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541267

2024-2032 年經前症候群治療市場報告（按藥物類型、類型、配銷通路和地區）

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2023年，IMARC Group經前症候群治療市場規模達13.97億美元。該市場的推動因素包括對精準醫療的日益關注，因為它可以提高患者的治療效果和治療效率，醫療保健支出的增加可以改善獲得護理的機會並擴大治療選擇，以及提高女性勞動力的參與度。

經前症候群治療市場分析：

主要市場促進因素：對精準醫療的需求不斷成長，加上醫療保健支出不斷增加，正在對市場產生正面影響。

主要市場趨勢：女性勞動參與度的提高和持續的技術進步正在刺激市場的成長。

地理趨勢：由於其強大的醫療基礎設施和強勁的經濟，北美佔據了最大的市場，從而提高了藥物的負擔能力。

競爭格局：經前症候群治療產業的一些主要市場參與者包括艾伯維公司、巴斯夫公司、拜耳公司、雷迪博士實驗室有限公司、禮來公司、葛蘭素史克公司、靈北公司、輝瑞公司.、鹽野義工業株式會社等。

挑戰與機會：雖然市場面臨對經前症候群缺乏認知和理解等挑戰，但它也遇到了開發新治療方案的機會。

經前症候群治療市場趨勢：

精準醫療日益受到關注

根據 IMARC 集團的報告，2023 年全球精準醫療市場規模將達到 752 億美元。在經前症候群的背景下，個體之間的症狀和嚴重程度可能存在很大差異，個人化的方法可以實現更有針對性和更有效的治療。此外，與經前症候群相關的遺傳因素或生物標記有助於為每位患者制定最有效的治療方案。這可以改善治療結果並減少治療選擇中的反覆試驗。除此之外，透過根據患者的遺傳或生理特徵匹配治療來選擇不太可能引起不良反應的藥物正在擴大市場成長。

醫療保健支出不斷增加

隨著醫療支出的增加，越來越多的人，包括受經前症候群困擾的女性，能夠尋求醫療協助，包括基層醫療醫師、婦科醫生和其他可以適當診斷和治療經前症候群的從業人員。此外，高醫療保健支出通常與其他更容易獲得經前症候群的治療選擇有關，其中包括荷爾蒙療法、抗憂鬱藥物等藥物治療，以及認知行為療法或生活方式改變等非藥物治療。高醫療保健支出為研發活動創造了更多機會，有助於找到更好的經前症候群療法。根據醫療保險和醫療補助服務中心網站2024年更新的內容，醫療保健支出佔GDP的比重預計將從2022年的17.3%成長到2032年的19.7%。

提高女性勞動參與度

根據世界銀行的數據，2023 年全球女性勞動參與率為 49%。由於其症狀，這對工作效率、出勤率和表現構成威脅。在意識到這些影響後，雇主和醫療保健提供者更有動力尋找有效的治療方法，以幫助減少經前症候群造成的工作場所干擾。此外，該公司正在投資工作場所健康計劃，其中包括對經前症候群等生殖健康問題的支持。這些計劃提供治療方法、圍繞症狀的靈活安排以及教育資源，所有這些都提高了對現有 PMS 治療方法的認知和使用。

經前症候群治療市場區隔：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據藥物類型、類型和配銷通路對市場進行了分類。

按藥物類型細分：

止痛藥

抗憂鬱藥

口服避孕藥和卵巢抑制劑

其他

鎮痛藥佔大部分市場佔有率

該報告根據藥物類型對市場進行了詳細的細分和分析。這包括止痛藥、抗憂鬱藥、口服避孕藥和卵巢抑制劑等。根據該報告，鎮痛藥佔最大的部分。

經前症候群是指在月經週期之前影響許多女性的幾種生理和心理症狀，例如腹痛、頭痛和肌肉疼痛。止痛藥受到廣泛青睞，因為它們可以快速緩解這些症狀，使其成為許多希望在月經週期中立即感到舒適的女性的首選。此外，人們開始意識到止痛藥在控制疼痛方面的功效，這推動了經前症候群治療市場對止痛藥的需求。

按類型分類：

處方

在櫃檯

場外交易佔據產業最大佔有率

報告還提供了基於類型的詳細市場細分和分析。這包括處方藥和非處方藥。報告稱，場外交易佔據最大的市場佔有率。

用於治療經前症候群的非處方 (OTC) 產品包括止痛藥、利尿劑和其他補充劑，如鈣和鎂，無需醫生處方即可在櫃檯購買。這種可及性使女性能夠獨立治療症狀，而無需去看醫生。腹脹、痙攣、疲勞和情緒波動正成為經前症候群所導致的嚴重問題。非處方藥根據不同的症狀為這些問題提供了多種解決方案。非處方藥品牌的知名度以及從藥局、零售店和線上平台購買這些產品的便利性正在促進市場的成長。

按配銷通路分類：

醫院藥房

藥局和零售藥局

網路商店

藥局和零售藥局是主要的細分市場

該報告根據配銷通路對市場進行了詳細的細分和分析。這包括醫院藥房、藥局和零售藥房以及網路商店。根據該報告，藥局和零售藥局是最大的細分市場。

女性更喜歡藥局和藥房，因為她們可以買到各種非處方藥和補充劑來緩解經前症候群症狀。這確保了那些患有經前症候群的女性能夠以最快的方式得到緩解，而無需處方。 。其次，藥局和零售藥局為顧客提供多種品牌和形式的產品，可以幫助顧客根據自己的需求和症狀選擇所需的產品。這種多樣性提高了個人滿意度，並確保人們可以找到根據其特定需求量身定做的產品。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔據最大的經前症候群治療市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是經前症候群治療的最大區域市場。

加拿大健康資訊研究所網站上發表的一篇文章顯示，2023年加拿大醫療保健支出將達到3,440億加幣。女性，包括經前症候群。這包括改善獲得能夠有效診斷和治療經前症候群的醫療保健專業人員的機會，從而提高患者對該疾病的認知和認知。此外，北美的經前症候群發生率很高，這促使對有效治療解決方案的巨大需求。此外，該地區經濟強勁，導致醫療保健服務和藥物的負擔能力提高，進一步推動市場成長。

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。經前症候群治療產業的一些主要市場參與者包括艾伯維公司、巴斯夫公司、拜耳公司、雷迪博士實驗室有限公司、禮來公司、葛蘭素史克公司、靈北公司、輝瑞公司和鹽野義公司有限公司

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

主要參與者正在開發和引入新的藥物和治療方法來管理經前症候群症狀，擴大患者的治療選擇。他們正在進行研究並參與臨床試驗，以便更好地了解經前症候群機制、驗證治療效果並探索新的治療方法。此外，許多公司都專注於個人化醫療方法，根據患者個別特徵客製化治療方案，改善治療結果和患者滿意度。主要參與者參與宣傳工作，以提高對經前症候群的認知，提高診斷率，並向醫療保健提供者和患者提供有關可用治療方案的教育。他們專注於整合數位健康技術，例如症狀追蹤應用程式、穿戴式裝置和遠距醫療解決方案，以提高患者護理和治療效果。例如，2024 年，Samphire Neuroscience 新創公司籌集了 230 萬美元，利用神經科技穿戴裝置解決經前症候群和經期疼痛。

經前症候群治療市場新聞：

2023 年 9 月 12 日：後期臨床階段生物製藥公司 Vistagen 宣布 PH80 探索性 2A 期研究取得正面結果，該研究用於急性管理經前煩躁障礙 (PMDD) 症狀，包括負面情緒以及身體和行為症狀。

本報告回答的關鍵問題

  • 2023年全球經前症候群治療市場規模是多少
  • 2024-2032年全球經前症候群治療市場的預期成長率是多少
  • 推動全球經前症候群治療市場的關鍵因素是什麼
  • COVID-19 對全球經前症候群治療市場有何影響
  • 根據藥物類型，全球經前症候群治療市場的詳細情形如何
  • 全球經前症候群治療市場按類型分類是怎樣的
  • 基於配銷通路的全球經前症候群治療市場的細分是什麼
  • 全球經前症候群治療市場的重點區域有哪些
  • 誰是全球經前症候群治療市場的主要參與者/公司

本報告回答的關鍵問題

  • 2023年全球經前症候群治療市場規模有多大？ 2024-2032年全球經前症候群治療市場的預期成長率是多少？
  • 推動全球經前症候群治療市場的關鍵因素是什麼？
  • COVID-19 對全球經前症候群治療市場有何影響？
  • 根據藥物類型，全球經前症候群治療市場的詳細情形如何？
  • 全球經前症候群治療市場按類型分類是怎樣的？
  • 基於配銷通路的全球經前症候群治療市場的詳細情形如何？
  • 全球經前症候群治療市場的關鍵地區有哪些？
  • 全球經前症候群治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球經前症候群治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類型

  • 止痛藥
    • 市場趨勢
    • 市場預測
  • 抗憂鬱藥
    • 市場趨勢
    • 市場預測
  • 口服避孕藥和卵巢抑制劑
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按類型

  • 處方
    • 市場趨勢
    • 市場預測
  • 在櫃檯
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 藥局和零售藥局
    • 市場趨勢
    • 市場預測
  • 網路商店
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
Product Code: SR112024A4284

The global premenstrual syndrome treatment market size reached US$ 1,397.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,890.8 Million by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Analysis:

Major Market Drivers: The growing demand for precision medicine, along with the rising healthcare expenditure, is positively influencing the market.

Key Market Trends: Increasing female workforce participation and ongoing technological advancements are stimulating the growth of the market.

Geographical Trends: North America holds the largest segment because of its strong healthcare infrastructure and robust economy, which leads to greater affordability of medications.

Competitive Landscape: Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., SHIONOGI & Co. Ltd., among many others.

Challenges and Opportunities: While the market faces challenges like lack of awareness and understanding about PMS, it also encounters opportunities in the development of new treatment options.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the IMARC Group's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type, type, and distribution channel.

Breakup by Drug Type:

Analgesics

Antidepressants

Oral Contraceptives and Ovarian Suppression Agents

Others

Analgesics accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes analgesics, antidepressants, oral contraceptives and ovarian suppression agents, and others. According to the report, analgesics represents the largest segment.

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

Prescription

Over-the-Counter

Over-the-counter holds the largest share of the industry

A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes prescription and over-the-counter. According to the report, over-the-counter accounts for the largest market share.

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Drugs stores and retail pharmacies represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, drug stores and retail pharmacies, and online stores. According to the report, drugs stores and retail pharmacies represent the largest segment.

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Premenstrual Syndrome Treatment Market News:

September 12, 2023: Vistagen, a late clinical-stage biopharmaceutical company announced positive results from exploratory phase 2A study of PH80 for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.

Key Questions Answered in This Report

  • 1. What was the size of the global premenstrual syndrome treatment market in 2023?
  • 2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2024-2032?
  • 3. What are the key factors driving the global premenstrual syndrome treatment market?
  • 4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8. What are the key regions in the global premenstrual syndrome treatment market?
  • 9. Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players